Treatment of leishmaniasis is a challenging subject. Although available, chemotherapy is
limited, presenting toxicity and adverse effects. New drugs with antileishmanial activity are …

Background Treatment of cutaneous leishmaniasis (CL) remains challenging since the
drugs currently used are quite toxic, thus contributing to lethality unrelated to the disease …

Cutaneous leishmaniasis (CL) is not a life-threatening condition. However, its treatment can
cause serious adverse effects and may sometimes lead to death. Recently, safer local …

The standard of care for cutaneous leishmaniasis includes the intramuscular/intravenous
administration of pentavalent antimonials that are toxic and poorly tolerated. Primary health …

El objetivo de esta investigación fue describir el estado actual de la leishmaniosis en Costa
Rica, profundizar en las diferentes manifestaciones clínicas y en las especies identificadas …

Background Meglumine antimoniate (MA) remains the main treatment for cutaneous
leishmaniasis (CL). Uncontrolled studies suggest that intralesional MA (IL-MA) may be …

Cutaneous leishmaniasis (CL) is a high-morbidity, vector-borne disease endemic to
Colombia. Unlike conventional systemic antileishmanial therapy, intralesional meglumine …

Meglumine antimoniate (Glucantime) is a pentavalent antimonial used to treat
leishmaniasis, despite its acknowledged toxic effects, such as its ability to cause oxidative …

(CL) due to Leishmania (L.) Viannia (V.) braziliensis (LVb). The first recommendation
(strong, low certainty evidence) is to use intralesional (IL) pentavalent antimonial drugs …

One hundred and twenty-two lesions caused by Leishmania braziliensis in 92 patients were
treated using weekly intralesional (IL) infiltrations of a generic pentavalent antimonial …